Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOSAIC
NCT05933603Phase 2Active, not recruiting
- Sponsor
- University of Arizona
- Start
- Sep 2023
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atomoxetine and oxybutynin in obstructive sleep apnea (OSA), sponsored by University of Arizona. Primary endpoint: Obstructive Apnea-Hypopnea Index at 6 months. Started Sep 2023; status: active, not recruiting.
02
Drugs
atomoxetineoxybutynin
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT05933603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05933603.